Prudential Financial
SPRO icon

Prudential Financial’s Spero Therapeutics SPRO Stock Holding History

Prudential Financial’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-56,000
Closed -$40.3K – 2506
2025
Q1 		$40.3K Buy
56,000
+6,800
+14% +$5.74K ﹤0.01% 2215
2024
Q4 		$50.7K Buy
+49,200
New +$58.5K ﹤0.01% 2208
2024
Q2 		– Sell
-25,400
Closed -$43.7K – 2782
2024
Q1 		$43.7K Sell
25,400
-2,800
-10% -$4.39K ﹤0.01% 2604
2023
Q4 		$41.5K Hold
28,200
– – ﹤0.01% 2570
2023
Q3 		$34.1K Buy
28,200
+3,800
+16% +$5.26K ﹤0.01% 2536
2023
Q2 		$35.4K Buy
+24,400
New +$41.8K ﹤0.01% 2566
2023
Q1 		– Sell
-14,600
Closed -$25.3K – 2665
2022
Q4 		$25.3K Buy
+14,600
New +$27.3K ﹤0.01% 2555

Other funds holding SPRO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Prudential Financial's SPRO Position: Q2 2025 in Review

Prudential Financial sold out of Spero Therapeutics (SPRO) in Q2 2025, closing a stake of 56,000 shares — an estimated $40.3K sold.

Prudential Financial first reported a position in SPRO in Q4 2022 and held it in 7 quarters. The position peaked at $50.7K in Q4 2024. 44 funds tracked by Wall St. Rank hold SPRO as of Q2 2025.

  • Prudential Financial reported no remaining Spero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Prudential Financial sold 56,000 Spero Therapeutics shares in Q2 2025, an estimated $40.3K.
  • Prudential Financial first reported a position in Spero Therapeutics in Q4 2022 and held it in 7 quarters.
  • Prudential Financial's Spero Therapeutics position peaked at $50.7K in Q4 2024.
  • 44 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2025.

Based on Prudential Financial's 13F filing for Q2 2025, filed 12 Aug 2025.